ArticleFrontiers in aging2025
Estimation of biological aging based on T-cell differentiation trajectories: emerging and future avenues.
Article in Frontiers in aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The relationship between disease onset and chronological age varies between individuals, driving the need for a more accurate, universal biomarker of biological aging. Among the emerging alternatives, the immune system represents a universally shared, complex system that consistently shows aging-related decline across diverse individuals. Specifically, T-cell dynamics, capturing both thymic involution and lifelong antigenic exposure, provide insights into immune system aging. Although existing aging clocks, such as those based on DNA methylation (i.e., Horvath's and GrimAge), offer valuable predictions of biological age and disease risk, these methods are often limited in ability and cost to reflect real-time immune function. We also explore cutting-edge techniques to measure T-cell states, such as flow cytometry, single-cell omics, cytometry by time-of-flight (CyTOF), and the potential of non-invasive retinal imaging, but these techniques also face these limitations. To account for the challenges with the above-mentioned methods, we propose the naive-to-exhausted T-cell ratio as a promising, quantifiable metric of immune aging. The conceptual framework benchmarks the naive-to-exhausted T-cell ratio against established epigenetic clocks, generating an "immune age curve" that offers clinicians and researchers a practical approach to integrate immune aging assessments into clinical and preventative care. To test our hypothesis, we conducted survival association analysis based on naive-to-exhausted T-cell levels across all major cancers (including adrenal carcinoma (HR = 0.19 (CI [0.082, 0.44]),
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.